AsseSSing Impact in pSoriatic Treatment

CompletedOBSERVATIONAL
Enrollment

503

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions
Psoriatic Arthritis
Interventions
OTHER

Questionnaire

PsAID questionnaire

Trial Locations (21)

63000

CHU Gabriel-Montpied, Clermont-Ferrand

75651

GERPAL, Hopital de la Pitie, Paris

Unknown

Centre Hospitalier Le Mans, Le Mans

Hopitaux Universitaires de Marseille, Marseille

Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse

Klinikum Bamburg, Bamberg

Rheumatologische Schwerpunktpraxis, Berlin

Universitatsklinik Frankfurt, Frankfurt

Universitätsklinikum der Ruhr-Universität Bochum, Herne

MVZ für Rheumatologie Dr. Martin Welcker GmbH, Planegg

Ospedale Regionale Cardarelli, Campobasso

Complejo Universitario de a Coruña, A Coruña

Hospital Clinic (Barcelona), Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Central de Asturias, Oviedo

Hospital Universitario de Salamanca, Salamanca

M13 9WL

Manchester University NHS Foundation Trust, Manchester

OX39DU

Oxford University Hospital NHS Foundation Trust, Oxford

ST16 3SR

Midlands Partnership NHS Foundation Trust, Stafford

CF14 4HH

Cardiff and Vale University LHB, Cardiff

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Oxford

OTHER

NCT05171270 - AsseSSing Impact in pSoriatic Treatment | Biotech Hunter | Biotech Hunter